What is the clinical benefit of mediastinal lymph node dissection in stage IIIA operable NSCLC?
What is the clinical benefit of mediastinal lymph node dissection in stage IIIA operable NSCLC?
Introduction
Defining operable and inoperable disease in stage III
The management of Stage III NSCLC has been divided into sections dependent on whether the disease is considered operable or inoperable at the time of diagnosis.
This evidence relates to patients who have had standard therapy with at least lobectomy and lymph node sampling. Mediastinal lymph node staging, either by pre-operative (mediastinoscopy, endobronchial ultrasound FNA) or intra-operative sampling is an integral part of surgical resection of NSCLC. Besides the prognostic value of proper staging, the current evidence base for adjuvant chemotherapy shows a survival advantage for patients receiving chemotherapy if any nodes are found to be positive.
Complete lymph node dissection versus lymph node staging in stage IIIA
Whilst accurate lymph node staging should be standard practice, the evidence to date has been unclear as to when a complete mediastinal lymph node dissection is indicated, if at all. In a Cochrane review by Manser et al[1], it was found that the evidence already existed for a survival benefit from complete mediastinal lymph node dissection. This was specifically reported in 2006[2], but did not generate the level of interest that accompanies new pharmacological interventions. The randomised trials by Wu et al[3] and Passlick et al[4] showed an increasing benefit for higher stage disease, but the Will Rogers phenomenon of stage migration could not be ruled out as a source of bias. It was not until the publication of the American College of Surgeons Oncology Group Z30 trial[5], that it could be inferred that the benefit of complete mediastinal dissection is clearest in stage II and higher NSCLC. A further systematic review and meta analysis by Huang et al[6] included patients with all stages of NSCLC and found no difference in overall survival between complete mediastinal lymph node dissection and systematic lymph node sampling. However this analysis was heavily weighted towards very early pathologic Stage I patients by inclusion of the ACOSOG Z30 trial.[5]
Evidence summary and recommendations
Evidence summary | Level | References |
---|---|---|
Complete mediastinal lymph node dissection is associated with improved overall survival compared to lymph node staging alone in patients with unknown stage or stage II-IIIA surgically resected NSCLC.
Last reviewed November 2015 |
I, II | [1], [2], [7], [3], [4], [6] |
References
- ↑ 1.0 1.1 Manser R, Wright G, Hart D, Byrnes G, Campbell DA. Surgery for early stage non-small cell lung cancer. Cochrane Database Syst Rev 2005 Jan 25;(1):CD004699 Available from: http://www.ncbi.nlm.nih.gov/pubmed/15674959.
- ↑ 2.0 2.1 Wright G, Manser RL, Byrnes G, Hart D, Campbell DA. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. Thorax 2006 Jul;61(7):597-603 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16449262.
- ↑ 3.0 3.1 Wu Y, Huang ZF, Wang SY, Yang XN, Ou W. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer 2002 Apr;36(1):1-6 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11891025.
- ↑ 4.0 4.1 Passlick B, Kubuschock B, Sienel W, Thetter O, Pantel K, Izbicki JR. Mediastinal lymphadenectomy in non-small cell lung cancer: effectiveness in patients with or without nodal micrometastases - results of a preliminary study. Eur J Cardiothorac Surg 2002 Mar;21(3):520-6 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11888774.
- ↑ 5.0 5.1 .
- ↑ 6.0 6.1 Huang X, Wang J, Chen Q, Jiang J. Mediastinal Lymph Node Dissection versus Mediastinal Lymph Node Sampling for Early Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. PLoS One 2014;9(10):e109979 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25296033.
- ↑ Hughes MJ, Chowdhry MF, Woolley SM, Walker WS. In patients undergoing lung resection for non-small cell lung cancer, is lymph node dissection or sampling superior? Interact Cardiovasc Thorac Surg 2011 Sep;13(3):311-5 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21606053.